Squadron Master Fund LP and related reporting persons filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 6,927,905 shares of Zentalis Pharmaceuticals, Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank each report beneficial ownership of 6,927,905 shares of Zentalis Pharmaceuticals common stock.
  • Percent of class: The 6,927,905 shares represent approximately 7.3% of Zentalis Pharmaceuticals common stock, according to the filing.
  • Share composition: The reported position consists of 6,827,905 shares of common stock plus 100,000 shares of common stock underlying long call options described as currently exercisable.
  • Shares outstanding basis: The percentage is calculated using 94,668,568 shares outstanding as of August 17, 2026, as reported by the issuer in a Prospectus filed August 14, 2026, plus the 100,000 option shares.
  • Voting and dispositive power: All 6,927,905 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as zero for all reporting persons.
  • Beneficial ownership disclaimer: According to the filing, Squadron Capital Management LLC, Mr. Sesterhenn, and Mr. Blank "expressly disclaim beneficial ownership of any of the securities reported in this statement."

Squadron Capital's Amended 13G Position in Zentalis Pharmaceuticals

The filing is Amendment No. 1 to a Schedule 13G covering Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) common stock, par value $0.001 per share, CUSIP 98943L107. The event triggering the amendment is dated September 30, 2026. Four reporting persons are named: Squadron Master Fund LP, a Delaware limited partnership; Squadron Capital Management LLC, a Delaware limited liability company; Matthew Sesterhenn; and William Blank.

According to the filing, Squadron Capital Management LLC is "an investment adviser registered under the Investment Advisers Act of 1940" and serves as investment adviser to Squadron Master Fund LP. The filing states that Mr. Sesterhenn and Mr. Blank, "as Partners of Squadron Capital Management, LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owners of all shares of Common Stock held by the Fund." The filing further notes that the Fund "has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by this Statement."

The 6,927,905 shares reported are composed of 6,827,905 shares of common stock and 100,000 shares of common stock underlying long call options held by Squadron Capital Management LLC that are described in the filing as "currently exercisable." The 7.3% ownership percentage is based on 94,668,568 shares outstanding as of August 17, 2026, as reported by Zentalis in a Prospectus filed with the SEC on August 14, 2026, plus the 100,000 option shares. All reporting persons list their business address as 1211 West 22nd Street, Suite 1008, Oak Brook, IL 60523.

What Was Disclosed

Squadron Master Fund LP and affiliated entities filed an amended Schedule 13G disclosing aggregate beneficial ownership of 6,927,905 shares, or approximately 7.3%, of Zentalis Pharmaceuticals common stock, with all voting and dispositive power held on a shared basis as of September 30, 2026.